ADMA Biologics (ADMA) Osake Kurssi
ADMA Biologics Kurssi
Viimeisten 13 vuoden aikana ADMA Biologicsn liikevaihto kasvoi 60,2 % vuodessa ja ylsi 510,17 M USD:een. ADMA Biologicsn nettomarginaali 28,8 % on noussut verrattuna −88,5 %:iin muutama vuosi sitten. ADMA Biologicsn 12 kuukauden konsensustavoitehinta on 18,00 USD, noin yli kurssia 62,5 %. 10 analyytikosta 8 suosittaa ostoa — kokonaiskonsensus on Osta.
ADMA Biologics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
ADMA Biologics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset ADMA Biologics -osakkeesta
ADMA Biologics Inc operates as a biopharmaceutical company. The company develops and produces specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases. ADMA Biologics focuses on the production and marketing of its hyperimmune globulin products, which are used to treat various medical conditions. With its emphasis on specialty plasma-derived products, ADMA Biologics Inc aims to improve patient outcomes and address unmet medical needs.
ADMA Biologics Inc is primarily active in the biopharmaceutical and healthcare industries.
The main competitors of ADMA Biologics Inc in the market include companies such as Grifols, CSL Ltd, and Octapharma.
ADMA Biologics Inc is a biopharmaceutical company specializing in the development and commercialization of plasma-derived products for the treatment of immune deficiencies and other infectious diseases. Founded in 2004, ADMA Biologics has evolved into a leading player in the immunoglobulin market. The company operates its own plasma collection centers and has a state-of-the-art fractionation facility located in Boca Raton, Florida. ADMA Biologics strives to deliver high-quality, plasma-derived products to patients with unmet medical needs. With a strong commitment to innovation and excellence, ADMA Biologics continues to expand its product pipeline and market presence, aiming to improve the lives of patients worldwide.
ADMA Biologics Inc has achieved significant milestones in its journey. The company has successfully gained FDA approval for its first plasma-derived biologic, RI-002™. In addition, they have expanded their product portfolio by launching BIVIGAM®, a treatment for primary humoral immunodeficiency, and ASCENIV™, a hyperimmune globulin. ADMA Biologics Inc also received FDA approval for acquisition of their BOC facility in Boca Raton, Florida, which has resulted in increased plasma collection capacity. These milestones have strengthened ADMA Biologics Inc's position in the market and reflect their commitment to providing innovative solutions and expanding their reach in the biopharmaceutical industry.
ADMA Biologics Inc is primarily present in the United States.
ADMA Biologics Inc represents a strong commitment to developing and delivering innovative plasma-derived products for the treatment of immune deficiencies and other infectious diseases. The company's corporate philosophy centers around maximizing patient access to life-saving therapies, ensuring product quality and safety, and fostering a culture of excellence in research and development. ADMA Biologics Inc values integrity, collaboration, and dedication to improving patient outcomes. Through its cutting-edge technologies and strategic partnerships, the company strives to address unmet medical needs and make a positive impact on global healthcare. ADMA Biologics Inc is dedicated to providing high-quality products and delivering value to patients, healthcare professionals, and stakeholders.
Analyytikot asettavat tällä hetkellä ADMA Biologics-osakkeelle keskimääräisen tavoitehinnan 18,67 USD (mediaani: 18,00 USD), mikä merkitsee +68,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä ADMA Biologics-osaketta: 8 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat ADMA Biologics-yhtiöltä 535,36 M USD liikevaihtoa ja 0,80 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla ADMA Biologics-osake noteerataan hintaan 9,88 EUR (11,08 USD).
ADMA Biologics-osake (ADMA) on listattuna 1 pörssissä, muun muassa: NASDAQ (ADMA).
ADMA Biologics Inc is a US biopharmaceutical company focused on the development of intravenous immunoglobulins (IVIG). The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics Inc's business model is based on the production and marketing of IVIG products for the treatment of primary immune deficiency diseases (PID). The company is divided into three business segments: manufacturing, sales and marketing of IVIG products, pipeline product development, and management of licenses and patents. ADMA Biologics Inc currently produces two IVIG products: BIVIGAM and ASCENIV. BIVIGAM is used to treat primary immune deficiency diseases, while ASCENIV is administered through intravenous push-injection. ADMA Biologics Inc is also working on developing additional IVIG products, and holds licenses and patents in the field of plasma proteins and related technologies. In summary, ADMA Biologics Inc's business model revolves around the production and marketing of IVIG products for the treatment of primary immune deficiency diseases. The company is involved in manufacturing, sales, and marketing of these products, as well as the development of new pipeline products. They also hold licenses and patents in the field of plasma proteins and related technologies.
odotettu liikevaihto ADMA Biologics on 535,36 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto ADMA Biologics on 195,11 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
ADMA Biologics:n hinta-voitto-suhde (P/E) on tällä hetkellä 13,85. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan ADMA Biologics-osakkeen arvostusta.
ADMA Biologics:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,05. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii ADMA Biologics-osakkeen arvostuskennuslukuna.
ADMA Biologics:n Eulpool-laatuscore on 7/10.
ADMA Biologics:n ISIN on US0008991046. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
ADMA Biologics:n WKN on A12FAG. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
ADMA Biologics:n ticker on ADMA. Tämä pörssinoteeraus käytetään ADMA Biologics-osakkeiden kauppaan pörssissä.
ADMA Biologics osake
ADMA Biologics vertaisryhmä
ADMA Biologics Ticker
ADMA Biologics FIGI
Kaikki tunnusluvut ja syvällinen analyysi ADMA Biologics:sta
Meidän osakeanalyysimme ADMA Biologics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut ADMA Biologics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: